Nanobiotix to present at H.C. Wainwright on Sept. 15
Rhea-AI Filing Summary
Nanobiotix S.A. (NBTX), a late-stage clinical biotechnology company, reported that its management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 15, 2026 at 12:00 pm EDT / 6:00 pm CEST.
The session will feature Chief Executive Officer Laurent Lévy and Chief Financial and Business Officer Bart Van Rhijn. Nanobiotix highlights its portfolio of more than 30 umbrella patents across three nanotechnology platforms in oncology, bioavailability and biodistribution, and central nervous system disorders.
Positive
- None.
Negative
- None.
Key Figures
Conference date: September 15, 2026
Conference time (EDT): 12:00 pm EDT
Conference time (CEST): 6:00 pm CEST
+5 more
8 metrics
Conference date
September 15, 2026
Date of Nanobiotix fireside chat at H.C. Wainwright 28th Annual Global Investment Conference
Conference time (EDT)
12:00 pm EDT
Scheduled time of the Nanobiotix fireside chat
Conference time (CEST)
6:00 pm CEST
Corresponding European time for the Nanobiotix session
Number of umbrella patents
More than 30
Umbrella patents associated with Nanobiotix’s three nanotechnology platforms
Number of nanotechnology platforms
3
Platforms with applications in oncology, bioavailability and biodistribution, and central nervous system disorders
Year incorporated
2003
Year Nanobiotix was incorporated
Euronext Paris listing year
2012
Year Nanobiotix was listed on Euronext Paris
Nasdaq Global Select Market listing date
December 2020
Date Nanobiotix was listed on the Nasdaq Global Select Market
Key Terms
foreign private issuer, nanotechnology platforms, bioavailability and biodistribution, forward-looking statements, +1 more
5 terms
foreign private issuer regulatory
"Form 6-K report of foreign private issuer pursuant to Rule 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
nanotechnology platforms technical
"more than 30 umbrella patents associated with three (3) nanotechnology platforms"
bioavailability and biodistribution medical
"applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders"
forward-looking statements regulatory
"This press release contains “forward-looking” statements within the meaning"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
cash runway projections financial
"include the risk that assumptions underlying the Company’s cash runway projections"
FAQ
What did Nanobiotix (NBTX) announce in this Form 6-K?
Nanobiotix announced that management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 15, 2026, with the presentation scheduled for 12:00 pm EDT / 6:00 pm CEST.
Who will present for Nanobiotix (NBTX) at the H.C. Wainwright conference?
The presenters will be Laurent Lévy, Chief Executive Officer of Nanobiotix, and Bart Van Rhijn, Chief Financial and Business Officer, taking part in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference.
When and where is Nanobiotix’s (NBTX) conference fireside chat taking place?
The Nanobiotix fireside chat is scheduled for Tuesday, September 15, 2026 at 12:00 pm EDT / 6:00 pm CEST during the H.C. Wainwright 28th Annual Global Investment Conference in New York.
What kind of company is Nanobiotix (NBTX)?
Nanobiotix is described as a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches, with more than 30 umbrella patents linked to nanotechnology platforms in oncology, bioavailability and biodistribution, and central nervous system disorders.
On which SEC annual report form does Nanobiotix (NBTX) file?
Nanobiotix files its annual reports with the SEC under Form 20-F, as indicated in the foreign private issuer report.
AI-generated analysis. How Rhea-AI works. Not financial advice.
